Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Archer

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Obstetrics and Gynecology|October 11, 2018
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled TrialBruce R Carr, Elizabeth A Stewart, David F Archer, et al.
Menopause (New York, N.Y.)|June 27, 2008
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause SocietyWulf H Utian, David F Archer, Gloria A Bachmann, et al.
Maturitas|March 16, 2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label studyFernand Labrie, David F Archer, Céline Bouchard, et al.
Contraception|August 6, 2019
Comparison of self-reported female condom failure and biomarker-confirmed semen exposureTerri L Walsh, Margaret C Snead, Breione J St Claire, et al.
American Journal of Obstetrics and Gynecology|July 24, 2020
Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroidsAyman Al-Hendy, Linda Bradley, Charlotte D Owens, et al.
The Lancet. Global Health|June 25, 2019
Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trialsDavid F Archer, Ruth B Merkatz, Luis Bahamondes, et al.
Obstetrics and Gynecology|May 28, 2020
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine LeiomyomasJames A Simon, Ayman Al-Hendy, David F Archer, et al.
Eclinicalmedicine|July 22, 2022
Continuation rates of two different-sized copper intrauterine devices among nulliparous women: Interim 12-month results of a single-blind, randomised, multicentre trialDavid Hubacher, Courtney A Schreiber, David K Turok, et al.
The New England Journal of Medicine|January 24, 2020
Elagolix for Heavy Menstrual Bleeding in Women with Uterine FibroidsWilliam D Schlaff, Ronald T Ackerman, Ayman Al-Hendy, et al.
The New England Journal of Medicine|May 20, 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH AntagonistHugh S Taylor, Linda C Giudice, Bruce A Lessey, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Obstetrics and Gynecology|October 11, 2018
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled TrialBruce R Carr, Elizabeth A Stewart, David F Archer, et al.
Menopause (New York, N.Y.)|June 27, 2008
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause SocietyWulf H Utian, David F Archer, Gloria A Bachmann, et al.
Maturitas|March 16, 2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label studyFernand Labrie, David F Archer, Céline Bouchard, et al.
Contraception|August 6, 2019
Comparison of self-reported female condom failure and biomarker-confirmed semen exposureTerri L Walsh, Margaret C Snead, Breione J St Claire, et al.
American Journal of Obstetrics and Gynecology|July 24, 2020
Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroidsAyman Al-Hendy, Linda Bradley, Charlotte D Owens, et al.
The Lancet. Global Health|June 25, 2019
Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trialsDavid F Archer, Ruth B Merkatz, Luis Bahamondes, et al.
Obstetrics and Gynecology|May 28, 2020
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine LeiomyomasJames A Simon, Ayman Al-Hendy, David F Archer, et al.
Eclinicalmedicine|July 22, 2022
Continuation rates of two different-sized copper intrauterine devices among nulliparous women: Interim 12-month results of a single-blind, randomised, multicentre trialDavid Hubacher, Courtney A Schreiber, David K Turok, et al.
The New England Journal of Medicine|January 24, 2020
Elagolix for Heavy Menstrual Bleeding in Women with Uterine FibroidsWilliam D Schlaff, Ronald T Ackerman, Ayman Al-Hendy, et al.
The New England Journal of Medicine|May 20, 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH AntagonistHugh S Taylor, Linda C Giudice, Bruce A Lessey, et al.
Pageof 18